Andy Kadlec

Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA.

Kosan Biosciences, Inc. develops drugs for cancer therapeutics. The company was founded in 1995 and is headquartered in New York, NY.

KAI Pharmaceuticals, Inc. discovers and develops biopharmaceutical drugs. It is a multiple, novel clinical-stage programs in the areas of cardiovascular, renal, and pain. The company was founded in 2002 and is headquartered in South San Francisco, CA.

Neurona Therapeutics, Inc. operates as a pre-clinical stage biotechnology company. It focuses on the discovery and development of cell-based therapies to treat intractable neurological disease. The company was founded by Arnold R. Kriegstein, John Rubenstein, Cory R. Nicholas, and Arturo Alvarez-Buylla and is headquartered in South San Francisco, CA.

The Scripps Research Institute is a private, non-profit research organizations that performs basic biomedical research in molecular & cellular biology, chemistry, immunology and neuroscience. They receive the majority of its funding from federal agencies such as the National Institutes of Health. The organization also partners with pharmaceutical companies and is affiliated with the Scripps hospital group. The organization was founded in 1955 and is headquartered in La Jolla, California.

Keystone Capital Management LP (Keystone Capital) is a private equity firm founded in 1994 by Kent P. Dauten and Scott L. Gwilliam. The firm is headquartered in Chicago, Illinois.

Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto.

Northwestern University is a private institution founded in 1851 to serve the Northwest Territory, an area that now includes the states of Ohio, Indiana, Illinois, Michigan, Wisconsin and parts of Minnesota. Northwestern has three campuses

Trinity Biosystems, Inc. develops and formulates orally delivered bio-therapeutic macromolecules. It offers TriPex system, an approach to macromolecule delivery that works cooperatively with the natural physiology of the body. The system utilizes a specific and natural biological transport mechanism: a receptor-mediated transcellular transport pathway that allows passage through the mucosal epithelium and delivery of the therapeutic payload into the blood. The company was founded by Randall J. Mrsny on July 19, 2002 and is headquartered in Menlo Park, CA.

The Gordon and Betty Moore Foundation operate as a grantmaking organization works locally through its San Francisco Bay Area Program. It seeks to make a contribution to the quality of life in the bay area through targeted support in three areas: land protection, science and technology museums and the Betty Irene Moore Nursing Initiative. The company was founded by Gordon and Betty Moore in 2000 and is headquartered in San Francisco, CA.

Junior Achievement of Wisconsin, Inc. provides education services to children and young people. The firm offers in-school and after-school programs for students in grades K-12. The company is headquartered in Milwaukee, WI.

The Column Group LLC is a venture capital firm founded in 2005 by Peter Svennilson. The firm is headquartered in San Francisco.

Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA.

Merck Research Ventures (Merck Research) is a venture capital subsidiary of Merck Research Laboratories Massachusetts LLC founded in 2000. The firm is headquartered in Cambridge, Massachusetts.

Kallyope, Inc. engages in developing drugs and consumer products. Its specialties include biotechnology, gut-brain axis, nutrition, and pharmaceuticals. The company was founded by Thomas P. Maniatis, Charles Zuker and Richard Axel in 2014 and is headquartered in New York, NY.

Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA.

Vida Ventures LLC invests in companies located in the United States. The fund targets companies operating in the fields of life science innovation. It provides financing for seed, early and later stage capital requirements.

VV Manager LLC (Vida Ventures) is a venture capital firm founded in 2017 by Arie Belldegrun, Arjun Goyal and Stefan Vitorovic. The firm is headquartered in Boston, Massachusetts.

Caraway Therapeutics, Inc. provides heathcare services. The company was founded by Timothy Harris, Wade Harper ,Ivan Dikic ,Tony Hyman and is headquartered in Cambridge, MA.

Plexium, Inc. provides drug development methodology services. It specializes in immunomodulation as a therapeutic approach for CNS and oncology. The company was founded by Brian Paegel on July 12, 2017 and is headquartered in San Diego, CA.

Synthekine, Inc. engages as a biotechnology company. The company is headquartered in Menlo Park, CA.

Tallac Therapeutics, Inc. engages in the development of immunomodulating polynucleotides. The company is headquartered in Burlingame, CA.

Nura Bio, Inc. develops neuroprotective drugs. The company is headquartered in South San Francisco, CA.

Ambagon Therapeutics, Inc. provides healthcare services. It specializes in biotechnology. The company is headquartered in San Francisco, CA.

AlivaMab Discovery Services LLC is a private company that specializes in generating and screening large panels of antibodies to achieve their partners' design goals. AlivaMab Discovery Services is based in San Diego, CA. The company focuses on delivering antibodies that are characterized for function, kinetics, and developability, and engineering for advanced modalities, including multispecifics and cars. The company has experience in antibody drug discovery and development from many of the world's top pharmaceutical companies, including AbbVie, AstraZeneca, Bristol Myers Squibb, Novartis, Pfizer, and Roche/Genentech. The company was founded by John Lippincott, and the CEO is Larry L. Green.

Mozart Therapeutics, Inc. is a company focused on developing first-in-class disease-modifying therapies for autoimmune and inflammatory diseases, with a therapeutic focus on autoimmune mediated gastro-intestinal disorders. The company is based in Seattle, WA. The company utilizes a novel approach to restoring immune system function by targeting the CD8 T regulatory network. Mozart Therapeutics is advancing a pipeline of first-in-class ‘CD8 Treg modulators’ designed to restore durable immune balance. The CEO of the company is Katie Fanning.

Cajal Neuroscience is a biotechnology company that focuses on discovering new treatments for neurodegeneration. The company is based in Seattle, WA and was founded by Ian Peikon. The company uses advanced technologies such as integrative human genetics, multi-omics, functional genomics, and microscopy to accelerate their target and drug discovery.

Part of Xilio Therapeutics, Inc., Xilio Therapeutics LLC develops cancer biopharmaceuticals. The company is based in Waltham, MA. The CEO of the company is René Russo.

Kimia Therapeutics, Inc. is a drug discovery company that utilizes high throughput precision chemistry, genome editing, and machine learning to identify druggable sites for human disease intervention. The private company is based in Berkeley, CA. The company is building a next-generation therapeutics discovery platform called Atlas, which combines active learning with automated synthesis and screening. Atlas is powered by a high-throughput, nano-liter scale chemistry platform that provides Kimia with instant access to billions of drug-like compounds. The CEO of the company is Stig K. Hansen.